Enveric Biosciences Inc (ENVB) Stock Price, Quote & News

Company Profile

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuro...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 444 8400

Website: www.enveric.com

Address:

245 First Street, Riverview II 18 th Floor, Cambridge, United States

TwinTurboBul161 Aug. 4 at 4:23 PM

$BIVI $ENVB Sash

0 · Reply

TwinTurboBul161 Aug. 3 at 11:35 PM

$ENVB $STIM Watching14

0 · Reply

StockAlertzz Jul. 31 at 8:01 PM

$ENVB incoming soon $CALC both .. nice entry

0 · Reply

TradeMa Jul. 30 at 4:16 PM

$ENVB 7 days accumulation may complete soon. Then boom

0 · Reply

alifada Jul. 30 at 8:47 AM

$ENVB chart is promising!

0 · Reply

Gian22 Jul. 29 at 5:45 AM

$ENVB

0 · Reply

totti7 Jul. 27 at 2:36 PM

$ENVB What are the future stages to come? And the deadline?

0 · Reply

Trtrucking79 Jul. 20 at 5:12 PM

$ENVB you re still in a penny stock

0 · Reply

dcast Jul. 20 at 4:03 PM

$ENVB

1 · Reply

Luckyjs38 Jul. 17 at 1:15 PM

$ENVB Huge news inbound buckle up butter cups ♾️

0 · Reply

Enveric ‘welcomes’ final FDA guidance for psychedelic drug development

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Jun 16, 2026, 9:28 AM EDT - 7 weeks ago

Enveric Biosciences Announces Participation in 2026 BIO International Convention

Jun 9, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

2026-06-02T13:40:18.000Z - 2 months ago

Enveric Biosciences initiates IND-enabling Genotoxicity studies of EB-003

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

2026-05-19T12:19:47.000Z - 2 months ago

Enveric Biosciences reports preclinical results from analysis of EB-003

May 19, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

2026-05-15T13:30:05.000Z - 2 months ago

Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year

2026-05-15T13:28:31.000Z - 2 months ago

Enveric Biosciences sees cash runway into 1Q27

May 15, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

2026-05-13T16:39:18.000Z - 2 months ago

Enveric issued U.S. patent for methods of treating psychiatric disorders

May 13, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

2026-05-05T12:19:49.000Z - 3 months ago

Enveric Biosciences highlights preclinical data for EB-003

May 5, 2026, 8:00 AM EDT - 3 months ago

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

2026-04-30T19:26:43.000Z - 3 months ago

Enveric Biosciences trading resumes

2026-04-30T13:43:15.000Z - 3 months ago

Enveric Biosciences trading halted, volatility trading pause

Apr 28, 2026, 7:33 AM EDT - 3 months ago

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

LABT

2026-04-23T23:30:54.000Z - 3 months ago

Enveric Biosciences files to sell 6.82M shares of common stock

2026-04-21T17:19:08.000Z - 3 months ago

3 Penny Stocks to Watch Now, 4/21/26

PBM TOVX

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX GHRS HELP

Apr 17, 2026, 6:28 PM EDT - 3 months ago

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2026-04-17T00:05:12.000Z - 3 months ago

Enveric Biosciences prices $13.9M at-the-market offering

Apr 16, 2026, 8:00 PM EDT - 3 months ago

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2026-03-31T12:12:19.000Z - 4 months ago

Enveric Biosciences secures new U.S. patent for its EVM301 series

Mar 31, 2026, 8:00 AM EDT - 4 months ago

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Mar 27, 2026, 5:40 PM EDT - 4 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Enveric Biosciences Announces Registration of Five Trademarks

Feb 25, 2026, 8:00 AM EST - 5 months ago

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Feb 19, 2026, 8:00 AM EST - 5 months ago

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Jan 29, 2026, 8:00 AM EST - 6 months ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 28, 2026, 5:00 PM EST - 6 months ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 6 months ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 29, 2025, 8:00 AM EST - 7 months ago

Enveric Biosciences Announces Patent Issuance

Dec 12, 2025, 4:46 PM EST - 8 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 8 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 9, 2025, 8:00 AM EST - 8 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 4, 2025, 8:00 AM EST - 8 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Nov 26, 2025, 8:00 AM EST - 8 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 14, 2025, 4:05 PM EST - 9 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Enveric Biosciences Announces Reverse Stock Split

Oct 16, 2025, 8:30 AM EDT - 10 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 15, 2025, 8:00 AM EDT - 10 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 14, 2025, 9:00 AM EDT - 10 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 2, 2025, 8:45 AM EDT - 10 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Sep 18, 2025, 4:30 PM EDT - 11 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 11 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 8:00 AM EDT - 11 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 16, 2025, 8:45 AM EDT - 11 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Jul 23, 2025, 8:03 AM EDT - 1 year ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 15, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jun 24, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 16, 2025, 10:46 AM EDT - 1 year ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 10, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

May 28, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 20, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

TwinTurboBul161 Aug. 4 at 4:23 PM

$BIVI $ENVB Sash

0 · Reply

TwinTurboBul161 Aug. 3 at 11:35 PM

$ENVB $STIM Watching14

0 · Reply

StockAlertzz Jul. 31 at 8:01 PM

$ENVB incoming soon $CALC both .. nice entry

0 · Reply

TradeMa Jul. 30 at 4:16 PM

$ENVB 7 days accumulation may complete soon. Then boom

0 · Reply

alifada Jul. 30 at 8:47 AM

$ENVB chart is promising!

0 · Reply

Gian22 Jul. 29 at 5:45 AM

$ENVB

0 · Reply

totti7 Jul. 27 at 2:36 PM

$ENVB What are the future stages to come? And the deadline?

0 · Reply

Trtrucking79 Jul. 20 at 5:12 PM

$ENVB you re still in a penny stock

0 · Reply

dcast Jul. 20 at 4:03 PM

$ENVB

1 · Reply

Luckyjs38 Jul. 17 at 1:15 PM

$ENVB Huge news inbound buckle up butter cups ♾️

0 · Reply

2TrustHim Jul. 6 at 12:53 PM

$ENVB $3.00? Future Pipeline?

0 · Reply

Trade_Weaver Jul. 1 at 12:15 PM

$ENVB what does this stock have in the pipeline?

1 · Reply

SWEEN24 Jul. 1 at 12:43 AM

$ENVB in!

0 · Reply

2TrustHim Jun. 26 at 9:08 PM

$ENVB Is This Running To Another Level Next Week?

0 · Reply

TheFlash Jun. 25 at 5:25 PM

$ENVB tipranks.com/news/the-fly/psychedelic-definium-soars-on-study-results-for-lsd-based-depression-treatment-thefly-news

0 · Reply

TheFlash Jun. 25 at 5:20 PM

$ENVB Psychedelic: "Definium soars on study results for LSD-based depression treatment." Right up their alley. This will explode with news which should be soon. Chart at dead bottom.

0 · Reply

bioebi Jun. 24 at 11:50 PM

$ENVB $PLSM $CUPR $CDT ENVB: next 100% Runner Enveric Biosciences (NASDAQ: ENVB) operates with zero total debt and roughly $4.91M in cash. ENVB shares surged significantly (upwards of 140% to 160% in a single session) on news that the FDA was instructed to cut red tape around psychedelic drug approvals.Fast-Tracking Therapies: The directive directed the FDA to issue vouchers that could potentially cut the standard drug review time from 6-10 months down to 1-2 months.

1 · Reply

bioebi Jun. 24 at 11:46 PM

$ENVB $CDT $DAIC $MWYN ENVB: this is my next 100% Runner

1 · Reply

Luckyjs38 Jun. 22 at 4:54 PM

$ENVB

0 · Reply

andre82 Jun. 22 at 3:42 PM

$CNSY working on a fund that is 3x inverse performance of Mo tickers. The weighting of the tickers is correlated to how often they get tagged. Make the scammers work for you! 😂😂 $JAGX $NUWE $BDRX $ENVB

1 · Reply

Market Cap	5.78M
Revenue (ttm)	0.00
Net Income (ttm)	-8.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	147,390
Avg Vol	157,046
Day's Range	N/A - N/A
Shares Out	3.68M
Stochastic %K	92%
Beta	1.15
Analysts	Strong Buy
Price Target	$10.00